trial
as of 2026-07-01Efficacy of tDCS in the Treatment of Resistant Auditory Hallucinations in Schizophrenia
NCTId NCT04352569
at a glance
— · Unknown
Enrollment 44 (estimated)
Sponsored by Centre hospitalier de Ville-Evrard, France
Primary completion 2023-12-08
Synthesized from structured facts only — each point cited above.
Design & status
Phase
—
Status
Unknown
Enrollment
44 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2016-05-03
Primary completion
2023-12-08
Eligibility
ALL · 18 Years
Interventions & indications
Sponsors
Centre hospitalier de Ville-Evrard, FranceLead Sponsor
Investigators
1
NOOMANE BOUAZIZ, MDPrincipal Investigator
Sites
1 total
Neuilly-sur-Marne, France
Facts & assertions
4 sourced
Enrollment
44
Phase
NA
Primary Completion Date
2023-12-08
Status
UNKNOWN
relationships
The graph out of here
lead_sponsor
indication
investigator
person